Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea

Kyong Hwa Park, Jeong Sun Kim, Yong Park, Hee Yeon Seo, Young Je Park, In Keun Choi, Sang Cheul Oh, Jae Hong Seo, Chul Yong Kim, Kwang-Yoon Jung, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Nam-Joon Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC). However, optimal schedule and dosing of chemotherapy still need to be developed to reduce distant metastasis. This retrospective study was conducted to evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy (CCRT) regimen using cisplatin and 5-FU followed by adjuvant chemotherapy (AC) in patients with locoregioanlly advanced NPC. Methods: Forty-three NPC patients who had AJCC stage T3/T4 or N2/N3 and M0 disease were evaluated. The chemotherapy during CCRT consisted of cisplatin (75 mg/m2 on day 1) plus 5-FU (750 mg/m2/day on day 1-5), delivered every 4 weeks for two cycles. Three cycles of AC were given with cisplatin (75 mg/m2), epirubicin (37.5 mg/m2) on day 1, and bleomycin (7.5 mg/m2 bolus iv. on day 1 followed by 9 mg/m2 on day 1-5 by continuous infusion) every 3 weeks. Results: The overall response rate after CCRT was 95% (22 CRs and 19 PRs in 43) and 100% (16 CRs and 8 PRs in 24) after AC. Grade 3/4 neutropenia, mucositis, and weight loss were observed during CCRT phase in 18, 44, and 26% of patients, respectively. AC caused grade 3/4 neutropenia and emesis in 12.5 and 20.8% of patients, respectively. Conclusions CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities.

Original languageEnglish
Pages (from-to)643-651
Number of pages9
JournalCurrent Microbiology
Volume61
Issue number4
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Adjuvant Chemotherapy
Korea
Cisplatin
Fluorouracil
Neutropenia
Drug Therapy
Neoplasm Metastasis
Therapeutics
Epirubicin
Mucositis
Bleomycin
Vomiting
Nasopharyngeal carcinoma
Weight Loss
Appointments and Schedules
Retrospective Studies

Keywords

  • Adjuvant chemotherapy
  • Concomitant chemoradiation
  • Korea
  • Nasopharyngeal carcinomam
  • Retrospective analysis

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology

Cite this

Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. / Park, Kyong Hwa; Kim, Jeong Sun; Park, Yong; Seo, Hee Yeon; Park, Young Je; Choi, In Keun; Oh, Sang Cheul; Seo, Jae Hong; Kim, Chul Yong; Jung, Kwang-Yoon; Shin, Sang Won; Kim, Yeul Hong; Kim, Jun Suk; Lee, Nam-Joon.

In: Current Microbiology, Vol. 61, No. 4, 01.09.2010, p. 643-651.

Research output: Contribution to journalArticle

@article{8d9d088c859d4b518c360ef96cd7531c,
title = "Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea",
abstract = "Purpose: Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC). However, optimal schedule and dosing of chemotherapy still need to be developed to reduce distant metastasis. This retrospective study was conducted to evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy (CCRT) regimen using cisplatin and 5-FU followed by adjuvant chemotherapy (AC) in patients with locoregioanlly advanced NPC. Methods: Forty-three NPC patients who had AJCC stage T3/T4 or N2/N3 and M0 disease were evaluated. The chemotherapy during CCRT consisted of cisplatin (75 mg/m2 on day 1) plus 5-FU (750 mg/m2/day on day 1-5), delivered every 4 weeks for two cycles. Three cycles of AC were given with cisplatin (75 mg/m2), epirubicin (37.5 mg/m2) on day 1, and bleomycin (7.5 mg/m2 bolus iv. on day 1 followed by 9 mg/m2 on day 1-5 by continuous infusion) every 3 weeks. Results: The overall response rate after CCRT was 95{\%} (22 CRs and 19 PRs in 43) and 100{\%} (16 CRs and 8 PRs in 24) after AC. Grade 3/4 neutropenia, mucositis, and weight loss were observed during CCRT phase in 18, 44, and 26{\%} of patients, respectively. AC caused grade 3/4 neutropenia and emesis in 12.5 and 20.8{\%} of patients, respectively. Conclusions CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities.",
keywords = "Adjuvant chemotherapy, Concomitant chemoradiation, Korea, Nasopharyngeal carcinomam, Retrospective analysis",
author = "Park, {Kyong Hwa} and Kim, {Jeong Sun} and Yong Park and Seo, {Hee Yeon} and Park, {Young Je} and Choi, {In Keun} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Kim, {Chul Yong} and Kwang-Yoon Jung and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Nam-Joon Lee",
year = "2010",
month = "9",
day = "1",
doi = "10.1007/s00280-009-1203-6",
language = "English",
volume = "61",
pages = "643--651",
journal = "Current Microbiology",
issn = "0343-8651",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea

AU - Park, Kyong Hwa

AU - Kim, Jeong Sun

AU - Park, Yong

AU - Seo, Hee Yeon

AU - Park, Young Je

AU - Choi, In Keun

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Kim, Chul Yong

AU - Jung, Kwang-Yoon

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Lee, Nam-Joon

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Purpose: Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC). However, optimal schedule and dosing of chemotherapy still need to be developed to reduce distant metastasis. This retrospective study was conducted to evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy (CCRT) regimen using cisplatin and 5-FU followed by adjuvant chemotherapy (AC) in patients with locoregioanlly advanced NPC. Methods: Forty-three NPC patients who had AJCC stage T3/T4 or N2/N3 and M0 disease were evaluated. The chemotherapy during CCRT consisted of cisplatin (75 mg/m2 on day 1) plus 5-FU (750 mg/m2/day on day 1-5), delivered every 4 weeks for two cycles. Three cycles of AC were given with cisplatin (75 mg/m2), epirubicin (37.5 mg/m2) on day 1, and bleomycin (7.5 mg/m2 bolus iv. on day 1 followed by 9 mg/m2 on day 1-5 by continuous infusion) every 3 weeks. Results: The overall response rate after CCRT was 95% (22 CRs and 19 PRs in 43) and 100% (16 CRs and 8 PRs in 24) after AC. Grade 3/4 neutropenia, mucositis, and weight loss were observed during CCRT phase in 18, 44, and 26% of patients, respectively. AC caused grade 3/4 neutropenia and emesis in 12.5 and 20.8% of patients, respectively. Conclusions CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities.

AB - Purpose: Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC). However, optimal schedule and dosing of chemotherapy still need to be developed to reduce distant metastasis. This retrospective study was conducted to evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy (CCRT) regimen using cisplatin and 5-FU followed by adjuvant chemotherapy (AC) in patients with locoregioanlly advanced NPC. Methods: Forty-three NPC patients who had AJCC stage T3/T4 or N2/N3 and M0 disease were evaluated. The chemotherapy during CCRT consisted of cisplatin (75 mg/m2 on day 1) plus 5-FU (750 mg/m2/day on day 1-5), delivered every 4 weeks for two cycles. Three cycles of AC were given with cisplatin (75 mg/m2), epirubicin (37.5 mg/m2) on day 1, and bleomycin (7.5 mg/m2 bolus iv. on day 1 followed by 9 mg/m2 on day 1-5 by continuous infusion) every 3 weeks. Results: The overall response rate after CCRT was 95% (22 CRs and 19 PRs in 43) and 100% (16 CRs and 8 PRs in 24) after AC. Grade 3/4 neutropenia, mucositis, and weight loss were observed during CCRT phase in 18, 44, and 26% of patients, respectively. AC caused grade 3/4 neutropenia and emesis in 12.5 and 20.8% of patients, respectively. Conclusions CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities.

KW - Adjuvant chemotherapy

KW - Concomitant chemoradiation

KW - Korea

KW - Nasopharyngeal carcinomam

KW - Retrospective analysis

UR - http://www.scopus.com/inward/record.url?scp=78149344978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149344978&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1203-6

DO - 10.1007/s00280-009-1203-6

M3 - Article

C2 - 20033411

AN - SCOPUS:77955886353

VL - 61

SP - 643

EP - 651

JO - Current Microbiology

JF - Current Microbiology

SN - 0343-8651

IS - 4

ER -